Carl C. Peck

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

Carl C. Peck, William H. Barr, Leslie Z. Benet et al. · Clinical Pharmacology & Therapeutics · 1992 · 191 citations

Rational Drug Development, Pharmacological Study, Biochemistry +12

Extended least squares nonlinear regression: A possible solution to the “choice of weights” problem in analysis of individual pharmacokinetic data

Carl C. Peck, Stuart L. Beal, Lewis B. Sheiner et al. · Journal of Pharmacokinetics and Biopharmaceutics · 1984 · 159 citations

Pharmacokinetic Modeling, Possible Solution, Medicine +7

Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans

Lawrence J. Lesko, Malcolm Rowland, Carl C. Peck et al. · The Journal of Clinical Pharmacology · 2000 · 152 citations

Current Science, Therapeutic Area, Dermatopharmacology +18

Postmarketing drug dosage changes of 499 FDA‐approved new molecular entities, 1980–1999

James T. Cross, Howard Lee, Agnes Westelinck et al. · Pharmacoepidemiology and Drug Safety · 2002 · 137 citations

Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002)

Malcolm Rowland, L Balant, Carl C. Peck · AAPS PharmSci · 2004 · 129 citations · Full text